Innopharma Technology announces the worldwide release of the latest version of Eyepass particle analysis software and the upcoming launch of Eyecon2 for the Indian market at CPHI/P-MEC, Mumbai 21st to 23rd November.
DUBLIN, Ireland –Nov. 16, 2016 – Innopharma Technology announces the worldwide release of the latest version of Eyepass particle analysis software and the upcoming launch of Eyecon2 for the Indian market at CPHI/P-MEC, Mumbai 21st to 23rd November.
Eyecon™ 2 is a non-product contact particle characteriser of powder based processes for the pharmaceutical, chemical and food industries. Eyecon2 is used as a real-time, in-line or at-line particle size and shape monitoring process analytical technology (PAT) instrument. This unique system can be utilised for both batch and continuous processes, giving the user a deeper understanding of particle size distribution changes during processing and to allow process endpoint control based on particle size distribution (PSD) evaluation during formulation development, scale-up, technology transfer and commercial manufacturing.
“Eyecon2 embodies the insights we have gained from working with customers in delivering PAT solutions over the last number of years” said Dr Ian Jones, CEO and founder of Innopharma Labs Ltd. “Eyecon2 represents a significant enhancement of our capability in using direct imaging methodology for particle size measurement in applications such as fluid bed coating (Wurster), granulation (fluid bed, twin screw, roller compaction), milling and spheronising“.
Eyecon2 is the latest addition to the Innopharma Technology PAT family. The instrument is housed in a compact, lightweight stainless steel casing with quick release cabling for ease of movement and cleaning. Eyecon2 features a new optimised optical pathway resulting in an improved field of view and a wider particle size measurement range.
Eyecon2 also features the new ‘Eyepass™’ software which allows the user to quickly set up the instrument to measure a process. Eyepass software provides powerful report generation including D-Values, PSD, and captured images of particles. Eyepass enables U.S. FDA 21 CFR part 11 compliance and includes data integration capability via commonly used open platform communications (OPC).
More details on Eyepass and Eyecon2 are available on the Innopharma Technology website and will be launched to the India market at CPHI/P-MEC Mumbai 21st to 23rd November where the system will be shown on Glatt’s latest process equipment on stall J2, Hall 5.